Zogenix, Inc. (NASDAQ:ZGNX) Director Roger Hawley sold 63,203 shares of the stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $36.84, for a total value of $2,328,398.52. Following the transaction, the director now directly owns 105,575 shares of the company’s stock, valued at approximately $3,889,383. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Roger Hawley also recently made the following trade(s):

  • On Friday, December 8th, Roger Hawley sold 11,797 shares of Zogenix stock. The shares were sold at an average price of $37.02, for a total value of $436,724.94.

Zogenix, Inc. (ZGNX) traded up $0.35 during mid-day trading on Monday, hitting $37.05. The stock had a trading volume of 632,811 shares, compared to its average volume of 670,900. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23. Zogenix, Inc. has a 1-year low of $7.70 and a 1-year high of $42.60.

ZGNX has been the subject of a number of research analyst reports. Mizuho initiated coverage on Zogenix in a report on Wednesday, September 6th. They set a “buy” rating and a $28.00 target price for the company. ValuEngine cut Zogenix from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Stifel Nicolaus reissued a “buy” rating and set a $55.00 target price (up previously from $26.00) on shares of Zogenix in a report on Friday, September 29th. Zacks Investment Research raised Zogenix from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, William Blair upgraded Zogenix from a “market perform” rating to an “outperform” rating in a research report on Friday, September 29th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Zogenix has a consensus rating of “Buy” and a consensus price target of $42.67.

Hedge funds have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY grew its position in shares of Zogenix by 17.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 19,734 shares of the company’s stock valued at $214,000 after purchasing an additional 2,864 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Zogenix by 1,794.4% in the second quarter. JPMorgan Chase & Co. now owns 286,299 shares of the company’s stock valued at $4,152,000 after purchasing an additional 271,186 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Zogenix by 12.8% in the first quarter. Geode Capital Management LLC now owns 196,793 shares of the company’s stock valued at $2,135,000 after purchasing an additional 22,407 shares in the last quarter. Vanguard Group Inc. grew its position in Zogenix by 7.8% in the first quarter. Vanguard Group Inc. now owns 974,948 shares of the company’s stock worth $10,578,000 after acquiring an additional 70,617 shares during the period. Finally, Northern Trust Corp grew its position in Zogenix by 15.3% in the second quarter. Northern Trust Corp now owns 341,309 shares of the company’s stock worth $4,949,000 after acquiring an additional 45,219 shares during the period. Institutional investors and hedge funds own 73.43% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/roger-hawley-sells-63203-shares-of-zogenix-inc-zgnx-stock/1758185.html.

About Zogenix

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.